ATR Share Price Performance
US$140.17
-2.12 (-1.49%)
11.9% undervalued intrinsic discount
US$159.14
Fair Value
Price US$140.17
AnalystConsensusTarget US$159.14
AnalystLowTarget US$133.00
AnalystHighTarget US$213.03
Fair ValueUS$159.14
Share Pricen/a
AptarGroup, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
ATR Community Narratives
AN
Fair Value US$159.14 11.9% undervalued intrinsic discount
ATR: Expanded Partnership Agreements Will Drive Long-Term Healthcare Solutions
0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
Fair Value US$133 5.4% overvalued intrinsic discount
European Destocking And Litigation Will Mar Results But Spur Recovery
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$213.03 34.2% undervalued intrinsic discount
Rising Global Wellness Trends Will Unlock Biologics And Smart Packaging
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
European Destocking And Litigation Will Mar Results But Spur Recovery
Key Takeaways Margin pressures stem from shifts in packaging trends, normalization of key pharma products, and rising legal and sustainability-related costs dampening earnings and cash flow. Exposure to intense industry competition, evolving customer demands, and increased regulatory requirements threatens AptarGroup's long-term revenue growth and profitability.Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$133
5.4% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
4.35% p.a.
Profit Margin
10.5%
Future PE
23.47x
Price in 2029
US$162.66
ATR: Expanded Partnership Agreements Will Drive Long-Term Healthcare Solutions
Key Takeaways Proprietary drug delivery innovations and sustainable packaging recognition are driving revenue growth, margin expansion, and strengthening competitive positioning. Strategic expansion in Asia-Pacific and operational efficiency improvements are diversifying revenues, optimizing costs, and supporting long-term market leadership.Read more
85
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
AN
US$159.14
11.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
4.66% p.a.
Profit Margin
10.27%
Future PE
28.46x
Price in 2029
US$194.7
Rising Global Wellness Trends Will Unlock Biologics And Smart Packaging
Key Takeaways Growing focus on innovative drug delivery and systemic nasal therapies positions AptarGroup for expanding high-margin revenue streams and strategic partnerships in pharmaceuticals. Leadership in sustainable, personalized packaging and expansion in Asian markets drives long-term growth across beauty, closures, and health segments.Read more
1
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$213.03
34.2% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
5.28% p.a.
Profit Margin
9.83%
Future PE
39.11x
Price in 2028
US$260.48
Trending Discussion
Recently Updated Narratives
AN
ATR: Nasal And Eye Care Drug Delivery Platforms Will Support Balanced Outlook
Fair Value: US$133 5.4% overvalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ATR: Nasal And Eye Drug Delivery Platforms Will Support Attractive Future Returns
Fair Value: US$159.14 11.9% undervalued intrinsic discount
7 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
ATR: Share Repurchases And Nasal Drug Delivery Partnership Will Support Upside Potential
Fair Value: US$213.03 34.2% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
AptarGroup, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 30, 2026
- 6.10
- 37.19%
- 10.40%
- 53.7%
About ATR
- Founded
- 1992
- Employees
- 14000
- CEO
- WebsiteView website
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations, as well as closures, such as dispensing and non-dispensing solutions that enable product delivery without removal of the cap and used across various consumer end markets. The company also offers aerosol valves used in pressurized containers and continuous spray and metered-dose valves for pharmaceutical, personal care, and household applications; elastomeric primary packaging components; active material science solutions; and digital health solutions. The company primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
